A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
1 other identifier
interventional
459
13 countries
133
Brief Summary
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jul 2007
Longer than P75 for phase_3
133 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 26, 2007
CompletedFirst Posted
Study publicly available on registry
October 29, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2018
CompletedResults Posted
Study results publicly available
June 24, 2019
CompletedJune 24, 2019
May 1, 2019
10.9 years
October 26, 2007
May 29, 2019
May 29, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)
Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug)
From first to last study drug dose plus 30 days
Study Arms (1)
Pimavanserin tartrate (ACP-103)
EXPERIMENTALTablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Interventions
Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Eligibility Criteria
You may qualify if:
- Subject has completed the treatment period of a previous blinded study of pimavanserin
- The subject is willing and able to provide consent
- Caregiver is willing and able to accompany the subject to all visits
You may not qualify if:
- Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder
- Subject is judged by the Investigator to be inappropriate for the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (135)
Unknown Facility
Gilbert, Arizona, 85234, United States
Unknown Facility
Phoenix, Arizona, 85013, United States
Unknown Facility
Tucson, Arizona, 84724, United States
Unknown Facility
Berkeley, California, 94705, United States
Unknown Facility
Carson, California, 90746, United States
Unknown Facility
Fountain Valley, California, 92708, United States
Unknown Facility
Fresno, California, 93720, United States
Unknown Facility
Irvine, California, 92697, United States
Unknown Facility
La Habra, California, 90631, United States
Unknown Facility
La Jolla, California, 92037, United States
Unknown Facility
Laguna Hills, California, 92653, United States
Unknown Facility
Loma Linda, California, 92354, United States
Unknown Facility
Oxnard, California, 93030, United States
Unknown Facility
Pasadena, California, 91105, United States
Unknown Facility
Reseda, California, 91335, United States
Unknown Facility
Sunnyvale, California, 94085, United States
Unknown Facility
Ventura, California, 93003, United States
Unknown Facility
Englewood, Colorado, 80113, United States
Unknown Facility
Danbury, Connecticut, 06810, United States
Unknown Facility
Fairfield, Connecticut, 06824, United States
Unknown Facility
Farmington, Connecticut, 06030, United States
Unknown Facility
Boca Raton, Florida, 33486, United States
Unknown Facility
Bradenton, Florida, 34205, United States
Unknown Facility
Deerfield Beach, Florida, 33064, United States
Unknown Facility
Gainesville, Florida, 32610, United States
Unknown Facility
Jacksonville, Florida, 32209, United States
Unknown Facility
Miami, Florida, 33136, United States
Unknown Facility
Naples, Florida, 34102, United States
Unknown Facility
Orlando, Florida, 32806, United States
Unknown Facility
Ormond Beach, Florida, 32174, United States
Unknown Facility
Panama City, Florida, 32405, United States
Unknown Facility
Pompano Beach, Florida, 33060, United States
Unknown Facility
Port Charlotte, Florida, 33980, United States
Unknown Facility
Sarasota, Florida, 34233, United States
Unknown Facility
St. Petersburg, Florida, 33701, United States
Unknown Facility
Tampa, Florida, 33606, United States
Unknown Facility
Augusta, Georgia, 30912, United States
Unknown Facility
Decatur, Georgia, 30033, United States
Unknown Facility
Glenview, Illinois, 60026, United States
Unknown Facility
Springfield, Illinois, 62794, United States
Unknown Facility
Kansas City, Kansas, 66160, United States
Unknown Facility
Louisville, Kentucky, 40202, United States
Unknown Facility
Scarborough, Maine, 04074, United States
Unknown Facility
Baltimore, Maryland, 21287, United States
Unknown Facility
Boston, Massachusetts, 02215, United States
Unknown Facility
Worcester, Massachusetts, 01655, United States
Unknown Facility
Clinton Township, Michigan, 48037, United States
Unknown Facility
Detroit, Michigan, 48201, United States
Unknown Facility
East Lansing, Michigan, 48824, United States
Unknown Facility
Roseville, Michigan, 48066, United States
Unknown Facility
Traverse City, Michigan, 49684, United States
Unknown Facility
West Bloomfield, Michigan, 48334, United States
Unknown Facility
Columbia, Missouri, 65201, United States
Unknown Facility
St Louis, Missouri, 63110, United States
Unknown Facility
Missoula, Montana, 59802, United States
Unknown Facility
Toms River, New Jersey, 08755, United States
Unknown Facility
Albany, New York, 12208, United States
Unknown Facility
Commack, New York, 11725, United States
Unknown Facility
Kingston, New York, 12401, United States
Unknown Facility
Rochester, New York, 14618, United States
Unknown Facility
Asheville, North Carolina, 28806, United States
Unknown Facility
Charlotte, North Carolina, 28204, United States
Unknown Facility
Durham, North Carolina, 27705, United States
Unknown Facility
New Bern, North Carolina, 28562, United States
Unknown Facility
Salisbury, North Carolina, 28144, United States
Unknown Facility
Cincinnati, Ohio, 45210, United States
Unknown Facility
Cleveland, Ohio, 44195, United States
Unknown Facility
Columbus, Ohio, 43210, United States
Unknown Facility
Toledo, Ohio, 43614, United States
Unknown Facility
Greensburg, Pennsylvania, 15601, United States
Unknown Facility
Philadelphia, Pennsylvania, 19131, United States
Unknown Facility
Providence, Rhode Island, 02906, United States
Unknown Facility
Brentwood, Tennessee, 37027, United States
Unknown Facility
Houston, Texas, 77030, United States
Unknown Facility
Salt Lake City, Utah, 84108, United States
Unknown Facility
Burlington, Vermont, 05401, United States
Unknown Facility
Alexandria, Virginia, 22311, United States
Unknown Facility
Richmond, Virginia, 23229, United States
Unknown Facility
Roanoke, Virginia, 24018, United States
Unknown Facility
Virginia Beach, Virginia, 23456, United States
Unknown Facility
Kirkland, Washington, 98034, United States
Unknown Facility
Spokane, Washington, 99204, United States
Unknown Facility
Milwaukee, Wisconsin, 53233, United States
Unknown Facility
Innsbruck, 6020, Austria
Unknown Facility
Vienna, 1090, Austria
Unknown Facility
Roeselare, 8800, Belgium
Unknown Facility
London, Ontario, N6A 5A5, Canada
Unknown Facility
Ottawa, Ontario, K1G 4G3, Canada
Unknown Facility
Clermont-Ferrand, 63003, France
Unknown Facility
Marseille, 13385, France
Unknown Facility
Nantes, 44093, France
Unknown Facility
Pessac, 33604, France
Unknown Facility
Strasbourg, 67091, France
Unknown Facility
Bangalore, 560 034, India
Unknown Facility
Chennai, 600 006, India
Unknown Facility
Hyderabad, 500003, India
Unknown Facility
Madurai, 625 020, India
Unknown Facility
Mangalore, 575 001, India
Unknown Facility
Mangalore, 575 002, India
Unknown Facility
Mumbai, 400 016, India
Unknown Facility
Mumbai, 400 026, India
Unknown Facility
Pune, 411 004, India
Unknown Facility
Pune, 411 030, India
Unknown Facility
Visakhapatnam, 530 002, India
Unknown Facility
Chieti, 66013, Italy
Unknown Facility
Grosseto, 58100, Italy
Unknown Facility
Rome, 00163, Italy
Unknown Facility
Rome, 00185, Italy
Unknown Facility
Bydgoszcz, 85796, Poland
Unknown Facility
Katowice, 40-752, Poland
Unknown Facility
Lublin, 20-090, Poland
Unknown Facility
Coimbra, 3000-548, Portugal
Unknown Facility
Lisbon, 1649-028, Portugal
Unknown Facility
Porto, 4099-001, Portugal
Unknown Facility
Kazan', 420061, Russia
Unknown Facility
Kirov, 610014, Russia
Unknown Facility
Moscow, 125284, Russia
Unknown Facility
Pyatigorsk, 357538, Russia
Unknown Facility
Saint Petersburg, 194044, Russia
Unknown Facility
Samara, 443095, Russia
Unknown Facility
Smolensk, 214018, Russia
Unknown Facility
Belgrade, 11000, Serbia
Unknown Facility
Novi Sad, 21000, Serbia
Unknown Facility
Stockholm, SE-112 45, Sweden
Unknown Facility
Kharkiv, 61068, Ukraine
Unknown Facility
Kiev, 04080, Ukraine
Unknown Facility
Kiev, 04114, Ukraine
Unknown Facility
Luhansk, 91045, Ukraine
Unknown Facility
Lviv, 79010, Ukraine
Unknown Facility
Vinnitsia, 21005, Ukraine
Unknown Facility
Barnsley, S75 2EP, United Kingdom
Unknown Facility
Blackburn, BB2 3HH, United Kingdom
Unknown Facility
London, NW3 20G, United Kingdom
Unknown Facility
Newcastle, NE4 6BE, United Kingdom
Unknown Facility
North Shields, NE21 8NH, United Kingdom
Related Publications (2)
Mathis MV, Muoio BM, Andreason P, Avila AM, Farchione T, Atrakchi A, Temple RJ. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. J Clin Psychiatry. 2017 Jun;78(6):e668-e673. doi: 10.4088/JCP.16r11119.
PMID: 28493654BACKGROUNDBallard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. J Am Med Dir Assoc. 2015 Oct 1;16(10):898.e1-7. doi: 10.1016/j.jamda.2015.06.021. Epub 2015 Aug 1.
PMID: 26239690DERIVED
MeSH Terms
Interventions
Results Point of Contact
- Title
- Sr. Dir. Medical Information and Medical Communications
- Organization
- ACADIA Pharmaceuticals Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 26, 2007
First Posted
October 29, 2007
Study Start
July 1, 2007
Primary Completion
May 30, 2018
Study Completion
May 30, 2018
Last Updated
June 24, 2019
Results First Posted
June 24, 2019
Record last verified: 2019-05
Data Sharing
- IPD Sharing
- Will not share